## Salem Billan

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/905673/publications.pdf

Version: 2024-02-01

1163117 752698 25 398 8 20 citations h-index g-index papers 25 25 25 625 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Precision medicine in head and neck cancer. Drug Resistance Updates, 2018, 40, 13-16.	14.4	121
2	Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Medical Oncology, 2012, 29, 704-706.	2.5	65
3	Perineural Spread in Noncutaneous Head and Neck Cancer: New Insights into an Old Problem. Journal of Neurological Surgery, Part B: Skull Base, 2016, 77, 086-095.	0.8	50
4	Treatment and Outcome of Patients with Skull Base Chordoma: A Meta-analysis. Journal of Neurological Surgery, Part B: Skull Base, 2014, 75, 383-390.	0.8	31
5	Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	24
6	<p>Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma</p> . OncoTargets and Therapy, 2020, Volume 13, 2289-2298.	2.0	21
7	Transoral Robotic Surgery in the HPV Era. Rambam Maimonides Medical Journal, 2014, 5, e0010.	1.0	16
8	Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer. Israel Medical Association Journal, 2013, 15, 231-5.	0.1	10
9	Trends in human papillomavirus–related oropharyngeal cancer in Israel. Head and Neck, 2016, 38, E274-8.	2.0	9
10	Nextâ€generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantageâ€"Multicenter experience. Head and Neck, 2020, 42, 599-607.	2.0	8
11	Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?. Medicine (United States), 2021, 100, e26388.	1.0	8
12	Crosstalk between Macrophages and Endothelial Cells in the Tumor Microenvironment. Molecular Therapy, 2021, 29, 895-896.	8.2	7
13	Hormone dependent metastatic salivary gland carcinoma: a case report. SpringerPlus, 2014, 3, 363.	1.2	5
14	Longâ€term outcomes in patients with nasopharyngeal carcinoma treated with reducedâ€volume conformal radiotherapy: A retrospective cohort study. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 562-567.	1.8	4
15	Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma. Anti-Cancer Drugs, 2022, 33, e760-e763.	1.4	3
16	Base of the tongue metastasis: aggressive behavior of triple-negative breast carcinoma. Israel Medical Association Journal, 2009, 11, 250.	0.1	3
17	Metastatic malignant struma ovarii. Israel Medical Association Journal, 2011, 13, 247-8.	0.1	3
18	American Funding Cutback to East Jerusalem Hospitals: A Blow to the Health of the City. American Journal of Public Health, 2018, 108, 1624-1625.	2.7	2

## SALEM BILLAN

#	Article	IF	CITATIONS
19	Building independence in health care and a partnership between nations. Lancet Oncology, The, 2018, 19, 869-870.	10.7	2
20	Developing an independent Palestinian cancer care capacity. Lancet Oncology, The, 2019, 20, 1485-1486.	10.7	2
21	Pembrolizumab–chemotherapy for advanced oesophageal cancer. Lancet, The, 2021, 398, 726-727.	13.7	2
22	Merkel cell carcinoma in lymph nodes with and without primary origin. Cancer Medicine, 2022, , .	2.8	1
23	Tyrosine kinase inhibitor treatment and long-term follow-up for metastatic malignant struma ovarii. Pediatric Hematology and Oncology, 2022, 39, 769-775.	0.8	1
24	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck Journal of Clinical Oncology, 2013, 31, 6065-6065.	1.6	0
25	Next Generation Sequencing in Salivary Gland Carcinomas: Do Actionable Mutations Lead to a Therapeutic Advantage? A Multicenter Experience Journal of Clinical Oncology, 2019, 37, e17582-e17582.	1.6	0